Luke T. Daum*† , Michael W. Shaw‡, Alexander I. Klimov‡, Linda C. Canas*, Elizabeth A. Macias*, Debra Niemeyer*, James P. Chambers†, Robert Renthal†, Sanjaya K. Shrestha§, Ramesh P. Acharya¶, Shankar P. Huzdar¶, Nirmal Rimal¶, Khin S. Myint#, and Philip Gould*
Author affiliations: *Air Force Institute for Operational Health, Brooks City Base, San Antonio, Texas; †University of Texas, San Antonio, Texas; ‡Centers for Disease Control and Prevention, Atlanta, Georgia; §Walter Reed/Armed Forces Research Institute of Medical Sciences Research Unit-Nepal, Kathmandu, Nepal; ¶Association of Medical Doctors of Asia-Nepal, Kathmandu, Nepal; #US Army Medical Component of the Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
Figure 3. . Three-dimensional top view of the HA1 hemagglutinin structures for A) a representative A/Nepal/1648/04 virus and B) vaccine strain A/Wyoming/3/03. Most (24/26) of the Nepal isolates contain a lysine to asparagine substitution (shown in yellow) at position 145 (K145N). Magenta, residues 226 and 227; orange, residue 189; green, residues 155 and 156; yellow, residue 145. Hemagglutinin molecules were generated by using the respective amino acid sequences with MOLMOL (12). A/Nepal/1648/04 is available from GenBank under accession no. AY945264.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.